Gwenn Hansen, Chief Scientific Officer at Nurix Therapeutics, sold NRIX on Aug 4, 2026
Data as of Oct 16
▼ SELL$35.8K1,500 shares at $23.87Gwenn Hansen Chief Scientific OfficerNRIX Nurix Therapeutics, Inc.
- Traded
- Aug 4, 2026
- Disclosed
- Aug 5, 2026
- Filed
- 1 day after the trade
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
NRIX since disclosure
−2.8%
after the sale
Similar stocks (XLV) since disclosure
+7.6%
XLV — its sector index fund
Change in closing price from Aug 5, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.
Other trades in the same filing
- ▼ SELLGwenn Hansen Chief Scientific OfficerNRIX Nurix Therapeutics, Inc.$64.3Kdisclosed Aug 5 · filed 1 day after the trade